Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Wednesday, May 27, 2020 at 8:00 a.m. ET to report interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma. Members of the Mersana executive team will be joined by investigator, Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute.
These data will include safety, tolerability and efficacy for new patients treated with 36 mg/m2 and 43 mg/m2. Further, these interim data will also report on the relationship between response and biomarker expression. With a cutoff date of May 1, 2020, the presentation will include 20 RECIST-evaluable ovarian cancer patients and 4 RECIST-evaluable NSCLC patients. Biomarker expression data will be available for the majority of evaluable patients. Additional patients are enrolled in the study but have not yet reached the RECIST evaluation timepoint.
Conference Call Details
About Mersana Therapeutics
Investor & Media Contact